All News

Hepatitis B (Keep)

AGA Guideline: Prevention and Treatment of Hepatitis B Virus Reactivation in At-Risk Individuals

Jack Cush, MD

The American Gastroenterology Association has published its revised clinical practice guidelines for the prevention and treatment of hepatitis B virus (HBV) reactivation in at-risk patients, particularly those with immune-mediated disease, receiving immunomodulatory therapy and steroids.

Read Article
RheumNow Podcast square

Weak Data (1.24.2025)

Jack Cush, MD

Dr. Jack Cush reviews the news and journal reports from RheumNow.com, and features Dr. Charity Dean, the Keynote speaker at RheumNow Live 2025, and why she is an inspiration.

Read Article
T%20cell.jpg

Functional Precision Medicine in Rheumatoid Arthritis

Jack Cush, MD

Novel research from the Medical University of Vienna demonstrates the plausible utility of functional precision medicine using immunophenotyping of blood cells with rheumatoid arthritis, to help guide treatment selection.

Read Article
RheumNow Podcast square

Fallen Angels (1.17.2025)

Jack Cush, MD

Dr. Jack Cush reviews the news and journal reports from the past week on RheumNow.com; and pays homage to colleagues who passed away in 2024.

Read Article
Covid lung pneumonia corona (keep)

Outcomes of Multisystem Inflammatory Syndrome in Children (MIS-C)

Jack Cush, MD

A nationwide cohort study of patients with multisystem inflammatory syndrome in children (MIS-C), a life-threatening complication of COVID-19 infection, showed that many had severe disease during the acute phase, but most recovered quickly and had a reassuring midterm prognosis.

Read Article
PMR,flag

BACHELOR Trial - Baricitinib in Early Polymyalgia Rheumatica

Jack Cush, MD

Lancet reports a French study demonstrating the efficacy of baricitinib in patients with polymyalgia rheumatica (PMR).

Read Article
DM.sine_.jpg

Dazukibart Effective in Adults with Dermatomyositis

Jack Cush, MD

Lancet reports that the use of dazukibart, a selective monoclonal antibody against interferon B (IFNβ), was clinically effective in reducing disease activity in adults with active dermatomyositis (DM).

Read Article
ACR Applauds Second Round of Medicare Drug Price Negotiations The ACR applauded the announcement of additional drugs subject to pricing negotiations with the CMS. This second round includes nintedanib (Ofev) and apremilast (Otezla), which are used to treat common and rare… https://t.co/z1LkpWMXqg https://t.co/hqjkqTqJxw
Dr. John Cush RheumNow ( View Tweet)
QD Clinic - An Undiagnosed Autoinflammatory Patient Autoinflammatory or Still's disease - does this matter? Features Dr. Jack Cush. QD Clinics - lessons from the clinic Sponsored by RNL2025 in Dallas, TX; Feb 8 & 9, 2025 Register at https://t.co/2dcFVgu8z6… https://t.co/UimGBUZMeO https://t.co/fkAg9gK0Im

Links:

Dr. John Cush RheumNow ( View Tweet)
Head-to-Head Clinical Trials https://t.co/tt8uLuLiV2 https://t.co/BvWxCGGN5V

Links:

Dr. John Cush RheumNow ( View Tweet)
Medicare has announced another 15 expensive drugs (now total 25) undergoing price negotiation with manufacturers. Enbrel and Stelara were in the 1st ten. Included in the next 15 Rx are Ofev (nintenib) & Otezla (apremilast) & GLP-1 drugs. https://t.co/SBwSprvo6K… https://t.co/okJXJCgOFm https://t.co/im2ggtgvt3

Links:

Dr. John Cush RheumNow ( View Tweet)
QD Clinic - Natural RA PsO/PsA patient avoiding DMARDs and Biologics, and wants Natural therapies Features Dr. Jack Cush QD Clinics - lessons from the clinic, sponsored by RNL2025 in Dallas, TX; Feb 8 & 9, 2025 Register at https://t.co/2dcFVgu8z6 https://t.co/nYhcPaC0qW https://t.co/wT80JoY4OE

Links:

Dr. John Cush RheumNow ( View Tweet)
Dazukibart Effective in Adults with Dermatomyositis Lancet reports that the use of dazukibart, a selective monoclonal antibody against interferon B (IFNβ), was clinically effective in reducing disease activity in adults with active dermatomyositis (DM).… https://t.co/7oRyxrFpar https://t.co/wA06Kzsdqg
Dr. John Cush RheumNow ( View Tweet)
Network metanalysis of 9 RCTs, 3699 patients looked at small molecule Rx in #PsA. With ACR 50/70, PASI 75, & HAQ-DI @ wk 12-16, UPA was > ADA in PASI75 (RR 1.2); Deucravacitinib > Otezla at HAQ (RR −0.16) no OTHER SIGNIF differences observed https://t.co/WQCFQDnnft https://t.co/7NTNIpzEuG

Links:

Dr. John Cush RheumNow ( View Tweet)
Eltrombopag, a Potential New Treatment for ITP A pilot trial has shown a thrombopoietin receptor agonist, eltrombopag (Promacta), to be effective in connective tissue disease-related (CTD), refractory immune thrombocytopenia (ITP). https://t.co/hYSAEKOjq5 https://t.co/QzBNA3SWVo

Links:

Dr. John Cush RheumNow ( View Tweet)
Alive in 2025 (1.10.2025) Dr. Jack Cush brings in the new year with a review of the latest from RheumNow. https://t.co/Cw94fF5nFi https://t.co/6c3Gl6GOCY

Links:

Dr. John Cush RheumNow ( View Tweet)
SetPoint Medical has applied to FDA for pre-market approval of Vagal nerve neuroimmune modulation device to Rx mod-severe #RA, not responding to 2 biologics. Based on RESET-RA 242 pt, 12 wk RCT showing ACR20=35% vs 24% PBO resp. SAE only 1.7%. https://t.co/d8RfXBFUSS https://t.co/Fq1qkfo1NM

Links:

Dr. John Cush RheumNow ( View Tweet)
Network metanalysis of 9 RCTs, 3699 patients looked at small molecule Rx in #PsA. With ACR 50/70, PASI 75, & HAQ-DI @ wk 12-16, UPA was > ADA in PASI75 (RR 1.2); Deucravacitinib > Otezla at HAQ (RR −0.16) no OTHER SIGNIF differences observed https://t.co/T0eMkXrxQX https://t.co/FCkbuhi1ze

Links:

Dr. John Cush RheumNow ( View Tweet)
FDA Approves First Generic of GLP-1 Receptor Agonist Victoza (liraglutide injection) to Lower Blood Sugar in Patients with Type 2 Diabetes https://t.co/1BYQFU2PsY https://t.co/jmbS9UDnhI

Links:

Dr. John Cush RheumNow ( View Tweet)
Anti-Zoster Drug Prevents Shingles in Lupus Patients on Anifrolumab The antiviral drug valaciclovir (Valtrex), given prophylactically, kept patients with SLE under treatment with anifrolumab (Saphnelo) from having herpes zoster attacks, researchers said, offering a potential… https://t.co/I3u8tK5EMq https://t.co/VItPWtrPUA
Dr. John Cush RheumNow ( View Tweet)
How well do you know this week's rheumatology news?
Take the rheumIQ quiz
Take the RheumIQ Quiz

×